Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Risdiplam may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Evrysdi contains the active substance risdiplam. It is part of a group of medicines known as 'premRNA splicing modifiers'. Evrysdi is used to treat spinal muscular atrophy (SMA), in adults and children. • •
SMA is an illness that runs in families – a genetic illness. It is caused by a shortage of a protein called 'survival motor neuron' (SMN) in the body.
If you do not have enough SMN protein, you lose motor neurons. Motor neurons are nerve cells that control muscles. • • •
This leads to muscle weakness and wasting. This can make everyday movements difficult, such as head and neck control, sitting, crawling and walking. The muscles used for breathing and swallowing may also become weaker.
How Evrysdi works 1 uk-pil-evrysdi-251202-clean-75mg-pos
Evrysdi works by helping the body produce more SMN protein.
increase how long they live reduce the need for a ventilator to help with breathing help them be able to keep being fed by mouth.
In children (toddlers to adolescents) and adults with SMA Type 2 and 3, Evrysdi may: stop muscle control getting worse
2.
improve muscle control.
e Evrysdi
Do not take Evrysdi: if you are allergic to risdiplam or any of the other ingredients of this medicine (listed in section 6). If you are not sure, talk to your doctor, pharmacist or nurse before you take Evrysdi. Warnings and precautions Talk to your doctor, pharmacist or nurse before you take Evrysdi. Treatment with Evrysdi may harm your unborn baby or may affect male fertility. See "Pregnancy", "Contraception", and "male fertility" for more information. Other medicines and Evrysdi Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines in the future. In particular tell your doctor, pharmacist or nurse if you are taking or have ever taken any of the following medicines: metformin – a medicine used to treat type 2 diabetes medicines for the treatment of SMA Pregnancy Before you start treatment with this medicine, your doctor should do a pregnancy test. This is because Evrysdi may harm your unborn baby.
Do not take this medicine if you are pregnant. Do not become pregnant: during your treatment with Evrysdi and for one month after you stop taking Evrysdi. If you do become pregnant during your treatment, tell your doctor straight away.
2 uk-pil-evrysdi-251202-clean-75mg-pos
You and your doctor will decide what is best for you and your unborn baby. Contraception For women You must use a highly effective method of birth control: while taking this medicine and for one month after you stop taking this medicine. Talk to your doctor about highly effective methods of birth control that you and your partner can use. For men If your partner is a woman who can have children, she must not become pregnant. Use condoms: while taking this medicine and for 4 months after you stop taking this medicine. Talk to your doctor about highly effective methods of birth control that you and your partner can use. Breast-feeding Do not breast-feed while taking this medicine. This medicine may pass into breast milk and may harm your baby. Talk to your doctor about whether you should stop breast-feeding or if you should stop taking Evrysdi. Male fertility Evrysdi may reduce male fertility during treatment and for up to 4 months after your last dose.
If you are planning to have a child, ask your doctor for advice. Do not donate sperm during your treatment and for 4 months after your last dose of this medicine.
Driving and using machines This medicine is unlikely to affect your ability to drive and use machines. Evrysdi contains sodium Evrysdi contains a small amount of sodium (salt) – there is less than 1 mmol (23 mg) sodium. This means it is essentially 'sodium-free' and can be used by people on a sodium-restricted diet. Evrysdi powder for oral solution contains 0.375 mg of sodium benzoate per mL. Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old). Evrysdi contains isomalt Evrysdi powder for oral solution contains 2.97 mg of isomalt per mL. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
3 uk-pil-evrysdi-251202-clean-75mg-pos
3.
How to take Evrysdi
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. If you get Evrysdi powder for oral solution, you should receive the medicine as a liquid in a bottle. Evrysdi is a liquid which is prepared by the pharmacist, and is referred to as a 'oral solution' or 'medicine' in this leaflet. Do not use if the medicine in the bottle is a powder, and contact your pharmacist. Evrysdi is also available as a film-coated tablet. Your doctor will help you choose the right one for you. How much Evrysdi to take Your doctor will choose the right dose of Evrysdi based on patient age and weight. You must take your daily dose as instructed by your doctor. Do not change the dose without speaking with your doctor. When and how to take Evrysdi A booklet with 'Instructions for use' is included in the pack. It shows you how to withdraw your dose using the re-usable oral syringe given to you. You can take the medicine: • by mouth, or • through a feeding tube You must also carefully read and follow the enclosed "Instructions for use" booklet on how to take or give Evrysdi. Take Evrysdi:
once a day at around the same time this will help you remember when to take your medicine. with or without food immediately after it is drawn up into the oral syringe. If it is not taken within 5 minutes, discard the medicine from the oral syringe, and withdraw a new dose Drink water after taking the medicine. Do not mix the medicine with milk or formula milk.
If Evrysdi gets on your skin, wash the area with soap and water. How long to take Evrysdi for Your doctor will tell you how long you need to take Evrysdi for. Do not stop treatment with Evrysdi unless your doctor tells you to. If you take more Evrysdi than you should If you take more Evrysdi than you should, talk to a doctor or go to hospital straight away.
4 uk-pil-evrysdi-251202-clean-75mg-pos
If you forget to take a dose: If it is less than 6 hours after you normally take Evrysdi, take the missed dose as soon as you remember. If it is over 6 hours from when you normally take Evrysdi, skip the missed dose and then take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose. If you are sick (vomit) after taking Evrysdi: Do not take an extra dose. Instead, take the next dose at the usual time the next day. If you spill Evrysdi If you spill this medicine, dry the area with a dry paper towel and then clean the area with soap and water. Throw away the paper towel in the rubbish and wash your hands well with soap and water. If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse. 4.
a dose of Evrysdi through a nasogastric tube (NG-tube)". Evrysdi's oral syringes are specifically designed to be compatible with the ENFit ® system. If your feeding tube is not ENFit® compatible, you may need an ENFit® transition connector to connect the Evrysdi syringe to your G-tube or NG-tube.
B) How to take a dose of Evrysdi by mouth Sit upright when taking a dose volume of Evrysdi by mouth. Step B1 Place the oral syringe into the mouth with the tip along either cheek. Slowly push the plunger all the way down to give the full dose of Evrysdi (See Figure J). Giving Evrysdi into the back of the throat or too fast may cause choking. Figure J
12 uk-pil-evrysdi-251202-clean-75mg-pos
Step B2 Check that there is no medicine left in the oral syringe (See Figure K).
Figure K
Step B3 Drink some water right after taking the dose of Evrysdi (See Figure L). Go to Step E for cleaning of the syringe.
Figure L
C) How to give a dose of Evrysdi through a gastrostomy tube If you are giving Evrysdi through a gastrostomy tube, ask your doctor or nurse to show you how to inspect the gastrostomy tube before giving Evrysdi.
Step C1 Place the oral syringe tip into the gastrostomy tube. Slowly push the plunger all the way down to give the full dose of Evrysdi (See Figure M).
Figure M
13 uk-pil-evrysdi-251202-clean-75mg-pos
Step C2 Check that there is no medicine left in the oral syringe (See Figure N).
Figure N
Step C3 Flush the gastrostomy tube with 10-20 mL of water right after giving the dose of Evrysdi (See Figure O). Go to Step E for cleaning of the syringe.
Figure O D) How to give a dose of Evrysdi through a nasogastric tube If you are giving Evrysdi through a nasogastric tube, ask your doctor or nurse to show you how to inspect the nasogastric tube before giving Evrysdi.
Step D1 Place the oral syringe tip into the nasogastric tube. Slowly press the plunger all the way down to give the full dose of Evrysdi (See Figure P). Figure P
Step D2 Check that there is no medicine left in the oral syringe (See Figure Q).
Figure Q
14 uk-pil-evrysdi-251202-clean-75mg-pos
Step D3 Flush the nasogastric tube with 10-20 mL of water right after giving the dose of Evrysdi (See Figure R). Go to Step E for cleaning of the syringe. Figure R
E) How to clean the oral syringe after use
Step E1 Remove the plunger from the oral syringe. Rinse the oral syringe barrel well under clean water (See Figure S).
Figure S
Step E2 Rinse the plunger well under clean water (See Figure T).
Figure T
15 uk-pil-evrysdi-251202-clean-75mg-pos
Step E3 Check that the oral syringe barrel and plunger are clean. Place the oral syringe barrel and plunger on a clean surface in a safe place to dry (See Figure U). Wash your hands. Once dry, reassemble the plunger into the oral syringe barrel and store the syringe with your medicine.
Figure U
16 uk-pil-evrysdi-251202-clean-75mg-pos
Instructions For Constitution Evrysdi 0.75 mg/mL powder for oral solution risdiplam Instructions for Constitution (FOR HEALTHCARE PROFESSIONALS [E.G.PHARMACISTS] ONLY) Each Evrysdi carton contains (See figure A): 1. 1 Cap 2. 1 Evrysdi bottle 3. 1 Oral syring 12 mL (in pouch) 4. 2 Oral syringes 6 mL (in pouches) 5. 2 Oral syringes 1 mL (in pouches) 6. 1 Press-in bottle adaptor 7. 1 Package Leaflet (not shown) 8. 1 Instructions for Constitution (not shown) 9. 1 Instructions for Use (not shown)
Figure A
Important information about Evrysdi
Avoid inhaling Evrysdi powder.
Use gloves.
Do not use if the powder expiry date has passed. The powder expiration date is printed on the bottle label.
Do not dispense the constituted solution if the solution's Discard After date exceeds the original powder expiration date.
Avoid getting contact with the medicine on your skin. If the medicine gets on your skin, wash the area with soap and water.
Do not use the medicine if any of the supplies are damaged or missing.
Use Purified Water or Water for Injection to constitute the medicine.
Do not add oral syringes other than the ones provided in the carton.
17 uk-pil-evrysdi-251202-clean-75mg-pos
Like all medicines, this medicine can cause side effects, although not everybody gets them. Very common: may affect more than 1 in 10 people diarrhoea rash headache fever Common: may affect up to 1 in 10 people feeling sick (nausea) mouth sores bladder infection joint pain Not known: it is not known how often these happen inflammed small blood vessels mainly in the skin (cutaneous vasculitis). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse.This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5.
How to store Evrysdi
Keep this medicine out of the sight and reach of children. Store the oral solution in a refrigerator (2 to 8 ̊C). If necessary, you may store the oral solution at room temperature (below 40 ̊C) for no more than a total of 120 hours (5 days). Return the oral solution to the refrigerator when it is no longer necessary to keep the bottle at room temperature. Monitor the total time outside the refrigerator (below 40 ̊C). As mentioned above, the sum of time intervals outside the refrigerator must not exceed 120 hours. The oral solution is stable for 64 days after the pharmacist prepares it when stored in the refrigerator at 2°C to 8°C. The pharmacist will write the date of expiration on the bottle label
5 uk-pil-evrysdi-251202-clean-75mg-pos
and on the original carton after "Discard after". Do not use the solution past this "Discard after" date or discard the medicine if the bottle has been stored at room temperature (below 40°C) for more than a total of 120 hours (5 days). Discard the medicine if the bottle has been stored for any period of time at above 40°C. Keep the medicine in the original bottle to protect from light. Keep the medicine bottle upright, with the cap tightly closed. Once you have drawn up the medicine into the oral syringe, use Evrysdi straight away. Do not store the Evrysdi solution in the syringe.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
Evrysdi
Store the powder (unconstituted medicine) at room temperature (< 25°C) and keep it in the carton with the bottle tightly closed in order to protect from moisture.
Store the solution (constituted medicine) in a refrigerator (2 to 8°C) and keep it in the carton upright.
Keep the oral solution in the original bottle and always keep the bottle in an upright position with the cap tightly closed.
Constitution
Step 1 Gently tap the bottom of the bottle to loosen the powder (See Figure B).
Figure B
Step 2 Remove the cap by pushing it down and then twisting to the left (counter-clockwise) (See Figure C). Do not throw away the cap.
Figure C
Step 3 Carefully pour 79 mL of Purified Water or Water for Injection into the medicine bottle (See Figure D).
Figure D
18 uk-pil-evrysdi-251202-clean-75mg-pos
Step 4 Hold the medicine bottle on a table with one hand. Insert the press-in bottle adaptor into the opening by pushing it down with the other hand. Ensure it is completely pressed against the bottle lip (See Figure E). Figure E Step 5 Put the cap back on the bottle. Turn the cap to the right (clockwise) to close the bottle. Ensure it is completely closed and then shake well for 15 seconds (See Figure F). Wait for 10 minutes. You should have obtained a clear solution. Afterwards, shake well again for another 15 seconds.
Figure F
Step 6 Calculate the Discard After date as 64 days after constitution (Note: the day of constitution is counted as day 0. For example, if constitution is on the 1st of April, the Discard After date will be the 4th of June). Write the Discard After date of the solution on the bottle label (See Figure G) and carton. Put the bottle back in its original carton, with syringes (in pouches), Package Leaflet and Instructions For Use booklet.
Figure G
Store the carton in the refrigerator (2 to 8°C).
19 uk-pil-evrysdi-251202-clean-75mg-pos
What Evrysdi contains
The active substance in the oral solution is risdiplam. Each mL of the oral solution contains 0.75 mg risdiplam. The other ingredients are mannitol (E 421), isomalt (E 953), strawberry flavour, tartaric acid (E 334), sodium benzoate (E 211), macrogol 6000 (E 1521), sucralose, ascorbic acid (E 300), disodium edetate dihydrate (see Section 2 'Evrysdi contains sodium' and 'Evrysdi contains isomalt').
What Evrysdi looks like and contents of the pack
Evrsydi powder for oral solution is delivered as an oral solution after preparation by the pharmacist. The solution is a greenish yellow to yellow, strawberry flavoured oral solution, the volume of the solution is 80 mL. Each carton contains 1 bottle, 1 press-in bottle adaptor, two 1-mL, two 6-mL and one 12-mL reusable amber oral syringes with markings to help you withdraw the right dose.
Marketing Authorisation Holder and Manufacturer Roche Products Limited 6 Falcon Way, Shire Park Welwyn Garden City AL7 1TW United Kingdom This leaflet was last revised in November 2025
6 uk-pil-evrysdi-251202-clean-75mg-pos
Instructions for Use – Administration Evrysdi 0.75 mg/mL powder for oral solution risdiplam Be sure to read and understand the Instructions for Use before you start using Evrysdi. These instructions show you how to prepare and give Evrysdi through an oral syringe, gastrostomy tube (G- tube), or nasogastric tube (NG-tube). If you have any questions about how to use Evrysdi, speak with your doctor or pharmacist. Evrysdi should come as a liquid in a bottle when you receive it. Evrysdi is prepared by a pharmacist into an oral solution. Do not use if the medicine in the bottle is a powder and contact your pharmacist.
7 uk-pil-evrysdi-251202-clean-75mg-pos
Important information about Evrysdi
Ask your doctor or pharmacist to show you which oral syringe you should use and how to measure your daily dose.
Always use the re-usable oral syringes in the pack to measure your daily dose.
Contact your doctor or pharmacist if your oral syringe(s) is/are lost or damaged. They will advise you about how to continue to take your medicine. See "How to select the correct oral syringe for your dose of Evrysdi". Ask your pharmacist if you have questions on how to select the right oral syringe.
If the bottle adaptor is not in the bottle, do not use Evrysdi and contact your pharmacist.
The oral solution may be stored at room temperature (below 40 ̊C) for no more than a total of 120 hours (5 days). Monitor the total time outside the refrigerator (below 40 ̊C).
Do not use Evrysdi after the Discard after date written on the bottle label or if you or your caregiver have stored the bottle at room temperature (below 40 ̊C) for more than a total of 120 hours (5 days). Ask your pharmacist for the Discard after date if it is not written on the bottle label.
Discard the medicine if the bottle has been stored for any period of time at above 40 ̊C.
Do not mix Evrysdi with milk or formula milk.
Do not use Evrysdi if the bottle or oral syringes are damaged.
Avoid getting Evrysdi on your skin. If Evrysdi gets on your skin, wash the area with soap and water.
If you spill Evrysdi, dry the area with a dry paper towel and then clean the area with soap and water. Throw away the paper towel in the waste and wash your hands well with soap and water.
If there is not enough Evrysdi left in the bottle for your dose, discard the bottle with remaining Evrysdi and used oral syringes according to your local requirements; use a new bottle of Evrysdi for your full dose. Do not mix Evrysdi from the new bottle with the bottle you are currently using.
Each EVRYSDI carton contains (See figure A): 1. 1 Evrysdi bottle with bottle adaptor and cap 2. 1 Oral Syringe 12 mL (in pouch) 3. 2 Oral syringes 6 mL (in pouches) 4. 2 Oral syringes 1 mL (in pouches) 5. 1 Instructions for Use booklet (not shown) 6. 1 Package Leaflet (not shown) Figure A
8 uk-pil-evrysdi-251202-clean-75mg-pos
How to store Evrysdi Please see section 5 "How to store Evrysdi" of the Package Leaflet for full information. A) Withdrawing your dose volume How to select the correct oral syringe for your dose of Evrysdi
If your daily dose of Evrysdi is between 0.3 mL and 1 mL, use a 1 mL oral syringe (yellow label).
If your daily dose of Evrysdi is between 1 mL and 6 mL, use a 6-mL oral syringe (grey label).
If your daily dose of Evrysdi is more than 6 mL, use a 12-mL oral syringe (brown label).
Ask your doctor or pharmacist about rounding your or your child's daily dose to the nearest syringe marking.
9 uk-pil-evrysdi-251202-clean-75mg-pos
How to withdraw your dose of Evrysdi
Step A1 Remove the cap by pushing it down and then twisting it to the left (counter-clockwise) (See Figure B). Do not throw away the cap.
Figure B
Step A2 Push the plunger of the oral syringe all the way down to remove any air in the oral syringe (See Figure C).
Figure C
Step A3 Keeping the bottle upright, insert the syringe tip into the bottle adaptor (See Figure D).
Figure D
Step A4 Carefully turn the bottle upside down with the syringe tip firmly inserted into the bottle adaptor (See Figure E).
Figure E
10 uk-pil-evrysdi-251202-clean-75mg-pos
Step A5 Slowly pull back on the plunger to withdraw your dose of Evrysdi. The top of the black plunger stopper must line up with the mL marking on the oral syringe for your daily dose (See Figure F). After you have drawn up the correct dose, hold the plunger in place to keep it from moving. Figure F
Step A6 Continue to hold the plunger in place to stop it moving. Leave the oral syringe in the bottle adaptor and turn the bottle to an upright position. Place the bottle onto a flat surface. Remove the oral syringe from the bottle adaptor by gently pulling straight up on the oral syringe (See Figure G). Figure G Step A7 Hold the oral syringe with the syringe tip pointing up. Check the medicine in the oral syringe. If there are large air bubbles in the oral syringe (See Figure H) or if you have drawn up the wrong dose of Evrysdi, insert the syringe tip firmly into the bottle adaptor. Push the plunger all the way down so that the medicine flows back into the bottle and repeat Steps A4 to A7. Take or give Evrysdi immediately after it is drawn up into the oral syringe. If it is not taken within 5 minutes, discard the medicine from oral syringe and withdraw a new dose.
Figure H
11 uk-pil-evrysdi-251202-clean-75mg-pos
Step A8 Put the cap back on the bottle. Turn the cap to the right (clockwise) to tightly close the bottle (See Figure I). Do not remove the bottle adaptor from the bottle.
Figure I If you are taking your dose of Evrysdi by mouth, follow the instructions in "B) How to take a dose of Evrysdi by mouth". If you are taking your dose of Evrysdi through a gastrostomy tube, follow the instructions in "C) How to give a dose of Evrysdi through a gastrostomy tube (G-tube)". If you are taking your dose of Evrysdi through a nasogastric tube, follow the instructions in "D)
Evrysdi 0.75 mg/mL powder for oral solution comes as oral solution containing 0.75mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Evrysdi 0.75 mg/mL powder for oral solution is risdiplam.
This leaflet reproduces the patient information leaflet approved for Evrysdi 0.75 mg/mL powder for oral solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
Treatment with Evrysdi should be initiated by a physician with experience in the management of SMA.
Posology
The recommended once daily dose of Evrysdi is determined by age and body weight (see Table 1).
Table 1. Evrysdi powder for oral solution dosing regimen by age and body weight
Age* and body weight
Recommended daily dose
< 2 months of age
0.15 mg/kg
2 months to < 2 years of age
0.20 mg/kg
≥ 2 years of age (< 20 kg)
0.25 mg/kg
≥ 2 years of age (≥ 20 kg)
5 mg
* based on corrected age for preterm infants
There is an alternative film-coated tablet dosage form available for patients ≥ 2 years of age with ≥ 20 kg body weight. Refer to the Evrysdi film-coated tablet summary of product characteristics (SmPC). The tablet or the tablet mixture should not be administered via a nasogastric (NG-tube) or gastrostomy tube (G-tube), but the powder for oral solution may be administered via a nasogastric or gastrostomy tube. The physician should prescribe the appropriate pharmaceutical form according to the dose required and the patient's needs, including the patient's ability to swallow. For patients with difficulty swallowing a whole tablet, the tablet can be dispersed or the powder for oral solution can be prescribed.
Treatment with a daily dose above 5 mg has not been studied.
Delayed or missed doses
If a planned dose is missed, it should be administered as soon as possible if still within 6 hours of the scheduled dose. Otherwise, the missed dose should be skipped and the next dose should be administered at the regularly scheduled time the next day.
If a dose is not fully swallowed or vomiting occurs after taking a dose of Evrysdi, another dose should not be administered to make up for the incomplete dose. The next dose should be administered at the regularly scheduled time.
Elderly
No dose adjustment is required in elderly patients based on limited data in subjects aged 65 years and older (see section 5.2).
Renal impairment
Risdiplam has not been studied in this population. No dose adjustment is expected to be required in patients with renal impairment (see section 5.2).
Hepatic impairment
No dose adjustment is required in patients with mild or moderate hepatic impairment. Patients with severe hepatic impairment have not been studied and may have increased risdiplam exposure (see sections 5.1 and 5.2).
Paediatric population
Use of Evrysdi for SMA in patients 2 months of age and younger is supported by pharmacokinetic and safety data from paediatric patients 16 days and older (see sections 4.8, 5.1 and 5.2). No data on risdiplam pharmacokinetics are available in patients less than 16 days of age.
Method of administration
Oral use.
Evrysdi powder for oral solution must be constituted by a healthcare professional (eg. pharmacist) prior to being dispensed.
It is recommended that a healthcare professional (HCP) discuss with the patient or caregiver how to prepare the prescribed daily dose prior to administration of the first dose.
Evrysdi is taken orally once a day with or without food at approximately the same time each day, using the re-usable oral syringe provided. Evrysdi should not be mixed with milk or formula milk.
Evrysdi should be taken immediately after it is drawn up into the oral syringe. If it is not taken within 5 minutes, it should be discarded from the oral syringe and a new dose be prepared. If Evrysdi spills or gets on the skin, the area should be washed with soap and water.
The patient should drink water after taking Evrysdi to ensure the medicinal product has been completely swallowed. If the patient is unable to swallow and has a nasogastric or gastrostomy tube in situ, Evrysdi powder for oral solution can be administered via the tube. The tube should be flushed with water after delivering Evrysdi.
Selection of the oral syringe for the prescribed daily dose:
Syringe size
Dosing volume
Syringe markings
1 mL
0.3 mL to 1 mL
0.01 mL
6 mL
1 mL to 6 mL
0.1 mL
12 mL
6.2 mL to 6.6 mL
0.2 mL
For the calculation of dosing volume, the syringe markings need to be considered. The dose volume should be rounded to the nearest graduation mark on the selected oral syringe.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Potential embryo-foetal toxicity
Embryo-foetal toxicity has been observed in animal studies (see section 5.3). Patients of reproductive potential should be informed of the risks and must use highly effective contraception during treatment and until at least 1 month after the last dose in female patients, and 4 months after the last dose in male patients. The pregnancy status of female patients of reproductive potential should be verified prior to initiating Evrysdi therapy (see section 4.6).
Potential effects on male fertility
Based on observations from animal studies, male patients should not donate sperm while on treatment and for 4 months after the last dose of Evrysdi. Prior to initiating treatment, fertility preservation strategies should be discussed with male patients of reproductive potential (see sections 4.6 and 5.3). The effects of Evrysdi on male fertility have not been investigated in humans.
Excipients
Isomalt
Evrysdi contains isomalt (2.97 mg per mL). Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Sodium
Evrysdi contains 0.375 mg of sodium benzoate per mL. Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).
Evrysdi contains less than 1 mmol sodium (23 mg) per 5 mg dose, i.e. is essentially 'sodium-free'.
Risdiplam is primarily metabolized by hepatic enzymes flavin monooxygenase 1 and 3 (FMO1 and 3), and also by cytochrome P450 enzymes (CYPs) 1A1, 2J2, 3A4, and 3A7. Risdiplam is not a substrate of human multidrug resistance protein 1 (MDR1).
Effects of other medicinal products on risdiplam
Co-administration of 200 mg itraconazole twice daily, a strong CYP3A inhibitor, with a single oral dose of 6 mg risdiplam did not exhibit a clinically relevant effect on the PK parameters of risdiplam (11% increase in AUC, 9% decrease in Cmax). No dose adjustments are required when Evrysdi is co-administered with a CYP3A inhibitor.
No drug-drug interactions are expected via the FMO1 and FMO3 pathway.
Effects of risdiplam on other medicinal products
Risdiplam is a weak inhibitor of CYP3A. In healthy adult subjects, oral administration of risdiplam once daily for 2 weeks slightly increased the exposure of midazolam, a sensitive CYP3A substrate (11% increase in AUC; 16% increase in Cmax). The extent of the interaction is not considered clinically relevant, and therefore no dose adjustment is required for CYP3A substrates.
In vitro studies have shown that risdiplam and its major human metabolite M1 are not significant inhibitors of human MDR1, organic anion-transporting polypeptide (OATP)1B1, OATP1B3, organic anion transporter 1 and 3 (OAT 1 and 3). However, risdiplam and its metabolite are in vitro inhibitors of the human organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion (MATE)1 and MATE2-K transporters. At therapeutic drug concentrations, no interaction is expected with OCT2 substrates. The effect of co-administration of risdiplam on the pharmacokinetics of MATE1 and MATE2-K substrates in humans is unknown. Based on in vitro data, risdiplam may increase plasma concentrations of medicinal products eliminated via MATE1 or MATE2-K, such as metformin. If co-administration cannot be avoided, drug-related toxicities should be monitored and dosage reduction of the co-administered medicinal product should be considered if needed.
There is no efficacy or safety data to support the concomitant use of risdiplam and nusinersen.
Patients of reproductive potential
Contraception in male and female patients
Male and female patients of reproductive potential should adhere to the following contraception requirements:
● Female patients of childbearing potential should use highly effective contraception during treatment and for at least 1 month after the last dose.
● Male patients, and their female partners of childbearing potential, should both ensure that highly effective contraception is achieved during treatment and for at least 4 months after the last dose.
Pregnancy testing
The pregnancy status of female patients of reproductive potential should be verified prior to initiating Evrysdi therapy. Pregnant women should be clearly advised of the potential risk to the foetus.
Pregnancy
There are no data from the use of Evrysdi in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).
Evrysdi is not recommended during pregnancy and in women of childbearing potential not using contraception (see section 4.4).
Breast-feeding
It is not known whether risdiplam is excreted in human breast milk. Studies in rats show that risdiplam is excreted into milk (see section 5.3). As the potential for harm to the breastfed infant is unknown, it is recommended not to breastfeed during treatment.
Fertility
Male patients
Male fertility may be compromised while on treatment, based on nonclinical findings. In rat and monkey reproductive organs, sperm degeneration and reduced sperm numbers were observed (see section 5.3). Based on observations from animal studies, the effects on sperm cells are expected to be reversible upon discontinuation of risdiplam.
Male patients may consider sperm preservation prior to treatment initiation or after a treatment-free period of at least 4 months. Male patients who wish to father a child should stop treatment for a minimum of 4 months. Treatment may be re-started after conception.
Female patients
Based on nonclinical data (see section 5.3), an impact of risdiplam on female fertility is not expected.
Evrysdi has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
In infantile-onset SMA patients, the most common adverse reactions observed in Evrysdi clinical studies were pyrexia (54.8%), rash (29.0%) and diarrhoea (19.4%).
In later-onset SMA patients, the most common adverse reactions observed in Evrysdi clinical studies were pyrexia (21.7%), headache (20.0%), diarrhoea (16.7%), and rash (16.7%).
The adverse reactions listed above occurred without an identifiable clinical or time pattern and generally resolved despite ongoing treatment in infantile-onset and later-onset SMA patients.
Based on the primary analysis of RAINBOWFISH, the safety profile of Evrysdi in pre-symptomatic patients is consistent with the safety profile of symptomatic infantile-onset and later-onset SMA patients. The RAINBOWFISH study enrolled 26 patients with pre-symptomatic SMA between 16 and 41 days of age at the time of the first dose (weight range 3.1 to 5.7 kg). The median exposure duration was 20.4 months (range: 10.6 to 41.9 months). Limited post-marketing data are available in neonates <20 days of age.
See also section 5.3 for the effects of Evrysdi observed in nonclinical studies.
Tabulated list of adverse reactions
The corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000). Adverse drug reactions from clinical studies (Table 2) are listed by MedDRA system organ class.
Table 2. Adverse drug reactions occurring in patients with infantile-onset and later-onset SMA based on Evrysdi clinical studies
System Organ Class
Infantile-onset SMA
(Type 1)
Later-onset SMA
(Type 2 and 3)
Gastrointestinal disorders
Diarrhoea
Very common
Very common
Nausea
Not applicable
Common
Mouth ulcerations and aphthous ulcers
Common
Common
Skin and subcutaneous tissue disorders
Rash*
Very common
Very common
Nervous system disorders
Headache
Not applicable
Very common
General disorders and administration site conditions
Pyrexia (including hyperpyrexia)
Very common
Very common
Infections and infestations
Urinary tract infection (including cystitis)
Common
Common
Musculoskeletal and connective tissue disorders
Arthralgia
Not applicable
Common
*Includes dermatitis, dermatitis acneiform, dermatitis allergic, erythema, folliculitis, rash, rash erythematous, rash maculo-papular, rash papular
Safety profile in patients previously treated with other SMA-modifying therapies
Based on the primary analysis of the JEWELFISH study, the safety profile of Evrysdi in SMA treatment non-naive patients who received Evrysdi for up to 59 months (including those previously treated with nusinersen [n=76] or with onasemnogene abeparvovec [n=14]) is consistent with the safety profile in SMA treatment-naive patients treated with Evrysdi in the FIREFISH, SUNFISH and RAINBOWFISH studies (see section 5.1).
Post-marketing experience
Cutaneous vasculitis was reported during post-marketing experience. Symptoms recovered after permanent discontinuation of Evrysdi. The frequency cannot be estimated based on available data.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There is no known antidote for overdosage of Evrysdi. In the event of an overdose, the patient should be closely supervised and supportive care instituted.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Evrysdi 0.75 mg/mL powder for oral solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.